IP Library Granted Patent US 9,289,501
Granted Patent B2
US 9,289,501 · App. 14/629,324 · Granted Mar 22, 2016

Carbonate prodrugs and methods of using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,289,501
App. No.
14/629,324
Granted
Mar 22, 2016
Kind
B2
Abstract

The present invention provides carbonate prodrugs which comprise a carbonic phosphoric anhydride prodrug moiety attached to the hydroxyl or carboxyl group of a parent drug moiety. The prodrugs may provide improved physicochemical properties over the parent drug. Also provided are methods of treating a disease or condition that is responsive to the parent drug using the carbonate prodrugs, as well as kits and unit dosages.

Claims (21)

1. A process for preparing a compound of the formula

or a pharmaceutically acceptable salt thereof,

comprising the steps of:

a) reacting a compound of the formula

with trifluoroacetic acid to provide the compound of the formula

 and

b) optionally converting the compound of the formula

to a pharmaceutically acceptable salt.

2. The process of claim 1 , wherein step a) uses acetic acid as a solvent.

3. The process of claim 1 , wherein step a) is performed at room temperature.

4. The process of claim 1 , wherein the compound of the formula

is formed from step a) within 30 minutes.

5. The process of claim 1 , wherein the compound of the formula

of step a) is prepared by reacting the compound of the formula

with di-tert-butyl hydrogen phosphate and triethylamine.

6. The process of claim 5 , wherein chloroform is used as a solvent in the preparation of the compound of formula

7. The process of claim 5 , wherein the compound di-tert-butyl hydrogen phosphate is prepared by reacting di-tert-butyl phosphite, potassium bicarbonate, and potassium permanganate.

8. The process of claim 7 , wherein water is used as a solvent in the preparation of di-tert-butyl hydrogen phosphate.

9. The process of claim 5 , wherein the compound of the formula

is prepared by reacting 4-acetominophenol, phosgene, and N,N-diethylaniline.

10. The process of claim 9 , wherein ethyl acetate is used as a solvent in the preparation of the compound of formula

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded May 31, 2017
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NEURONEX, INC.; CIVITAS THERAPEUTICS, INC.; ACORDA THERAPEUTICS, INC.
Reel/Frame 042643/0878 →
SECURITY INTEREST Recorded Jun 10, 2016
From: ACORDA THERAPEUTICS, INC.; CIVITAS THERAPEUTICS, INC.; NEURONEX, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 038950/0436 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2015
From: MUHAMMAD, NAWEED; BLEY, KEITH R.
To: NEUROGESX, INC.
Reel/Frame 037052/0303 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2015
From: NEUROGESX, INC.
To: ACORDA THERAPEUTICS, INC.
Reel/Frame 037115/0789 →